Identification

**Working Group on:** Cardiovascular Pharmacotherapy

**Nucleus Composition (Sept 2014-Sept 2016)**

*(Precise name, surname and country)*

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairperson</td>
<td>Stefan Agewall</td>
<td>Norway</td>
</tr>
<tr>
<td>Vice-chairperson &amp; Secretary</td>
<td>Basil S Lewis</td>
<td>Israel</td>
</tr>
<tr>
<td>Past Chairperson</td>
<td>Keld Kjeldsen</td>
<td>Denmark</td>
</tr>
<tr>
<td>Treasurer</td>
<td>Christian Torp-Pedersen</td>
<td>Denmark</td>
</tr>
<tr>
<td>Nucleus Members</td>
<td>Claudio Ceconi</td>
<td>Italy</td>
</tr>
<tr>
<td></td>
<td>Heinz Drexel</td>
<td>Austria</td>
</tr>
<tr>
<td></td>
<td>Christian Funck-Brentano</td>
<td>France</td>
</tr>
<tr>
<td></td>
<td>Juan Carlos Kaski</td>
<td>United Kingdom</td>
</tr>
<tr>
<td></td>
<td>Alexander Niessner</td>
<td>Austria</td>
</tr>
<tr>
<td></td>
<td>Juan Tamargo</td>
<td>Spain</td>
</tr>
<tr>
<td></td>
<td>Thomas Walther</td>
<td>Ireland</td>
</tr>
<tr>
<td>Ex-Officio Members</td>
<td>Giuseppe Rosano</td>
<td>Italy</td>
</tr>
<tr>
<td></td>
<td>Harald Schmidt</td>
<td>Netherlands</td>
</tr>
<tr>
<td></td>
<td>Sven Wassmann</td>
<td>Germany</td>
</tr>
<tr>
<td>Associate Members</td>
<td>Dan Atar</td>
<td>Norway</td>
</tr>
<tr>
<td></td>
<td>Maria Angeles Alonso Garcia</td>
<td>Spain</td>
</tr>
<tr>
<td></td>
<td>Faiez Zannad</td>
<td>France</td>
</tr>
</tbody>
</table>

**Elections in 2016**

Prof. Heinz Drexel was elected in February 2016 to take the position of Vice-Chair from September 2016

4 positions to replace:
Christian Funck-Brentano informed he nucleus that she would like to step down before the end of his manadate.
Keld Kjeldsen, Juan Tamargo, Christian Torp-Pedersen who have to step down in September 2016

Elected nucleus members are:

Prof. Giuseppe Rosano, FESC (United Kingdom)
Dr. Gianluigi Savarese, FESC (Italy)
Prof. Thomas Schmidt Denmark
Assoc. Prof. Sven Wassmann, FESC (Germany)
**Activities of the Working Group in 2014 - 2016**

**Meetings**

(For each meeting, please precise titles, dates, places, number of participants)

**WG Annual Meeting(s)**

1. New Trends in Cardiovascular Drug Therapy, May 30-June 1, 2014, Rome, Italy. This 2nd WG Annual Meeting was organized by Giuseppe Rosano and held in Rome, Italy, with 150 registered attendees. The scientific program was of high standard and well accepted, including poster presentations.

2. EuroCVP 2015, May 29-31, Rome, Italy. 3rd annual meeting of the WG was organized by Giuseppe Rosano. 100-140 attendees registered

3. WG session on Cardiovascular pharmacotherapy in the elderly, chairs Stefan Agewall and Basil Lewis at World Congress of Cardiology, Melbourne, Australia, May 6, 2014. The session was well attended by over 100 participants and the talks by Heinz Drexel, Dan Atar and Basil Lewis were well received.

4. EuroCVP 2016 – the 4th Annual Meeting of the WG - is planned for Tel Aviv, Israel on May 29-30, 2016. Joint sessions will be held with the HFA of the ESC, the WG for Thrombosis and the Council for hypertension. Responsible: Basil Lewis

**Endorsed Meeting(s)**

WG participation and endorsement at 20th ISCP (International Society for Cardiovascular Pharmacotherapy) annual meeting, Buenos Aires, Argentina, June 25-26, 2015. Keld Kjeldsen, Stefan Agewall and Basil Lewis participated in 2 joint sessions:

   a. ESC-ISCP Trial workshop training by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the International Society of Cardiovascular Pharmacotherapy: "Running cardiovascular trials efficiently and effectively"

   b. Joint Session ISCP-WG Pharma ESC: Challenges in CV Pharmacotherapy

Both sessions were attended by some 50 participants and the talks and discussion well received

**Education programme(s) – Training, Courses & Grants**

- **Workshops**

A series of very successful Trials Teaching Workshops were initiated in 2014 and continued in 2015. Responsible: Keld Kjeldsen
The first Trials Teaching Workshops were held at the 2nd WG Annual Meeting in Rome 2014, then at CVCT Asia, Singapore, July 6, 2014, in Moscow in April 2015 and at ISCP in Buenos Aires in June 2015.

- Educational Courses

An Educational Course initiative “All About Clinical Trials” was launched in 2015. These courses are planned to take place 3 times per year. Responsible: Sven Wassmann, Giuseppe Rosano.

The first course was held in London on March 27-28, 2015 and was attended by 25-30 registrants and was very well received. The second course was held on May 29-30 in Rome, Italy. The third course was held in Barcelona, Spain on 23-24 October, with 23 participants.

The courses were supported by Daiichi Sankyo and AMGEN. Recording of courses are available on the website of the WG.

In 2016, 4 courses are planned. The first was held in Brussels, Belgium on 19-20 March 2016 and was attended by 35 paying participants. The second will take place in conjunction with the annual meeting of the WG, in Tel Aviv, Israel. The 3rd course will be held in London in October 2016 and finally, if sponsorship is met, the 4th is foreseen in Berlin, Germany end of October. Daiichi has renewed its financial support.

Papers & Guidelines

(Please precise titles, authors and journal/issue where the paper is published)

Position Papers by the Working Group


**Guideline participation**

The WG has participated extensively in ESC guidelines
a. ESC/EACTS Guidelines in Myocardial Revascularisation
b. Acute Pulmonary Embolism
c. ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management
d. Ventricular Arrhythmias & Sudden Cardiac Death
e. Pulmonary Hypertension
f. Acute Coronary Syndromes NSTEMI
g. Pericardial Diseases
h. Infective Endocarditis
i. Dyslipidaemias
j. CVD Prevention
k. Atrial Fibrillation
l. Heart Failure

**Journal**

Official ESC WG Journal

- A new dedicated ESC WG journal European Heart Journal - Cardiovascular Pharmacotherapy (Stefan Agewall editor-in-chief, Dan Atar, Keld Kjeldsen and Basil Lewis associate editors) was launched in 2014. The journal is an addition to the European Heart Journal brand and is published by Oxford University Press. In 2015 4 issues will be published. Submissions are being received and due to high standard and demand, approximately 50% are already being rejected. Turn-around time is rapid: Submission to first decision averages 9.3 days and accepted manuscripts are published online within days. Listing in Medline and Pubmed is anticipated in 2016 and impact factor in 2017.
Sessions
(For sessions, please precise titles and accepted/rejected status)

**Sessions at ESC Annual meetings**

**Activities at ESC 2014**

Ten WG sessions have been accepted and will be presented at the scientific program of the ESC 2014 main congress in Barcelona.

1. Symposium: Important drug interactions – what you should know
2. Symposium: General surgery and cardiovascular drug benefits and risks
3. Symposium: Sudden death and pharmacotherapy
4. Symposium: Controversies in recent trials in acute coronary syndromes
5. Symposium: New insights in pharmacotherapy of peripheral circulation
7. Guideline session: Drug therapy: When guidelines do not have all the answers
8. Clinical seminar: Trials versus registries
9. Clinical seminar: Strategy trials: Important or impossible?
10. Clinical seminar: Cardiovascular safety of antidiabetic drugs

**Activities at ESC 2015**

The WG was involved in more than 10 sessions at ESC 2015 in London. The WG is planning for independent proposals from 2016 onwards.

**Activities of the Working Group for the coming year**

**Meetings**

1. ESC main Congress, Rome 2016
   Active Participation with proposals for scientific sessions

2. ESC WG Annual Congress
   EuroCVP 2017 – the 5th Annual Meeting of the WG to be discussed

In addition the WG will also hold a nucleus meeting, an extraordinary nucleus meeting, a position paper meeting and possibly also a strategy planning nucleus meeting.

**Workshops**

Trials Teaching Workshops are expected based on income/costs: CVCT USA in Dec 2016 and at ISCP in October 2016
Responsible: Keld Kjeldsen
Courses
The Educational Courses “All About Clinical Trials” will be continued in the next year.
Responsible: Sven Wassmann, Giuseppe Rosano

Journal and Textbook
An ESC WG Textbook of Cardiovascular Pharmacotherapy is in planning, with discussions led by Keld Kjeldsen. A book format together with an internet based/tablet format is a possibility, and the aim is symbiosis between journal and textbook. Oxford University Press has expressed their interest as publisher.

Position Papers / Reviews
A number of position papers / reviews are in preparation or being planned:


3. Relation between industry, scientists, approvals and guidelines
   Responsible: Giuseppe Rosano

4. Triple vs. double anticoagulant therapy in AF-ACS
   Responsible: Sven Wassmann

5. Potassium pharmacology
   Responsible: Keld Kjeldsen

Webpage
Webpage will be expanded to promote educational resources in keeping with ESC objectives.
Responsible: Alexander Niessner
Perspective for the next 3-5 years

Future projects / Business plan

- Strengthen the ESC WG journal – European Heart Journal – Cardiovascular Pharmacotherapy.
- Strengthen and expand the yearly scientific ESC WG meeting EuroCVP
- Continue to develop and expand Workshops, Courses, Textbook, Position Papers
- Increase the number of members of the WG
- Strengthen the finances of the WG

Budget

The financial state of the WG is sound

SWOT analysis of the Working Group

Strength

The nucleus of the WG consists of very ambitious, engaged and hard-working members, who all contribute to the projects of the WG
- We have started the annual ESC WG meeting
- We now have the ESC WG journal, which is a member of the very strong brand mark: European Heart Journal Family

Weakness

- Still a small number of members
- Limited budget

Opportunity

- The planned projects of the WG described above will increase the scientific influence of the WG during the years.
- Furthermore, the WG has a golden opportunity to strengthen the finances during the next years through the annual meeting, the ESC WG Journal, the Textbook, the Workshops and the Courses.

Threats

As well-known it is more difficult to attract sponsors from industry now and it is likely this tendency will remain. This fact may challenge the finances of the meeting and the journal
Recommendations/suggestions to the ESC for the next 2 years

The primary aim of ESC is not to earn money, rather to reduce the burden of cardiovascular disease in Europe.

Suggest an offensive approach for the next two years to strengthen the primary aim of ESC. Of course the budget needs to be in balance, but the solidity of ESC appears to be in good shape. Accelerate regarding CV activities but with less emphasis on finance.